{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"OR was defined as the number of participants who achieved a best response of either CR or PR per Grever and colleagues. CR: Near normalization of peripheral blood counts: hemoglobin \\>11 g/dL (without transfusion); platelets\\>100 000/μL; absolute neutrophil count \\>1500/μL. Regression of splenomegaly on physical examination. Absence of morphologic evidence of HCL on both the peripheral blood smear and the bone marrow examination. PR: PR required near normalization of the peripheral blood count (as in CR) with a minimum of 50% improvement in organomegaly and bone marrow biopsy infiltration with HCL.","groups":[{"description":"Participants with Relapsed/Refractory hairy cell leukemia received the following treatment during the study: Lymphodepletion chemotherapy regimen of fludarabine 30 mg/m\\^2/day IV and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3). A single IV infusion of brexucabtagene autoleucel at target dose of 2 × 10\\^6 anti-CD19 CAR T cells/kg on Day 0.","id":"OG000","title":"Substudy D (Relapsed/Refractory Hairy Cell Leukemia): Brexucabtagene Autoleucel"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants in substudy D, in the Modified Intent-to-Treat Analysis Set were analyzed.","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Substudy D: Number of Participants With OR Determined by Investigator Assessment Per Grever and Colleagues","type":"SECONDARY","unitOfMeasure":"Participants"}